Short profile
Name: Nalagenetics

Medical field: Cancer
Product type: Medical Devices, Diagnostics, and Therapeutics
Growth stage: Positioning for Scale
Team: 23 people

Description of product:
MammoReady™ is a DNA test to help patients understand their risks of developing breast cancer in the next 5 years based on three key risk analyses: monogenic, polygenic and clinical risk models. The test report also comes with actionable recommendations extracted from established guidelines.

Desired project goal: Please also elaborate on the primary outcome
Test-bedding of MammoReady™ as a risk stratification solution for breast cancer, with the project scope of (a) clinical validation, (b) pilot study and (c) cost-effectiveness study.
   (a) Validation of MammoReady™'s risk prediction model with application of several testing criteria, such as risk model discrimination and risk model predictive ability.
   (b) Pilot study (randomized clinical trial) mirroring GenoVA study in the US to assess clinical utility of MammoReady™ as a personalized risk screening tool compared to current standard of care.
   (c) Cost-effectiveness study of integrating MammoReady™ in the patient journey from the societal, payor and health sector perspectives compared to current standard of care.

Desired project type: Please also elaborate on the following points, if applicable: population, intervention, study design etc.
Test bedding and validation.